title: [Treatment of patients with radioiodine refractory, differentiated thyroid carcinoma. A Consensus Statement].
abstract: There is no clear standard therapy for patients with radioactive iodine (131I)-refractory locally advanced or metastatic differentiated thyroid cancer. The therapeutic options for this indication have expanded with the recently approved multiple kinase inhibitor sorafenib. Recommendations for the definition and the management of iodine refractory patients were worked up by an interdisciplinary expert panel, consisting of endocrine surgeons, medical oncologists and nuclear medicine specialists.
authors.affiliation: Christina Lindner, MSc, Department Life Sciences, Medizinische und Pharmazeutische Biotechnologie, IMC FH Krems, E-Mail: ch.lindner@fh-krems.eu.
authors.forename: Christina
authors.initials: C
authors.lastname: Lindner
authors.forename: J
authors.initials: J
authors.lastname: Dierneder
authors.forename: G
authors.initials: G
authors.lastname: Pall
authors.forename: C
authors.initials: C
authors.lastname: Pirich
authors.forename: M
authors.initials: M
authors.lastname: Hoffmann
authors.forename: M
authors.initials: M
authors.lastname: Raderer
authors.forename: A
authors.initials: A
authors.lastname: Becherer
authors.forename: B
authors.initials: B
authors.lastname: Niederle
authors.forename: R
authors.initials: R
authors.lastname: Lipp
authors.forename: P
authors.initials: P
authors.lastname: Lind
authors.forename: H
authors.initials: H
authors.lastname: Gallowitsch
authors.forename: F
authors.initials: F
authors.lastname: Romeder
authors.forename: I
authors.initials: I
authors.lastname: Virgolini
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D059248:Chemoradiotherapy / Q000592:standards; D019317:Evidence-Based Medicine; D005858:Germany; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008495:Medical Oncology / Q000592:standards; D009536:Niacinamide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D017410:Practice Guidelines as Topic; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D000077157:Sorafenib; D013964:Thyroid Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D007457:Iodine Radioisotopes; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D019275:Radiopharmaceuticals; D009536:Niacinamide; D000077157:Sorafenib
keywords: Radioactive iodine-refractoriness; sorafenib; thyroid cancer